Early Revolut backer invests in AI-focused finance software startup Light

Early Revolut backer invests in AI-focused finance software startup Light


Key Points
  • Light, a Danish financial software startup, told CNBC it has raised $30 million in a Series A funding round led by Balderton Capital.
  • Founded in 2022, Light’s software uses artificial intelligence to automate businesses’ accounting, bookkeeping and financial reporting.
  • The startup recently opened an office in London and is planning to open one in New York to meet U.S. demand



Source

Stocks making the biggest moves after hours: Cisco, Flutter Entertainment, Firefly and more
Finance

Stocks making the biggest moves after hours: Cisco, Flutter Entertainment, Firefly and more

Check out the companies making headlines in after-hours trading. Cisco — Shares of Cisco gained more than 7% in extended trading after the networking company posted better-than-expected profit and revenue for its fiscal first quarter. Cisco earned $1 per share, excluding items, on $14.88 billion in revenue, while analysts polled by LSEG expected 98 cents […]

Read More
Boston Fed President Collins advocates holding rates steady, sees ‘high bar’ for further cuts
Finance

Boston Fed President Collins advocates holding rates steady, sees ‘high bar’ for further cuts

Key Points Boston Fed President Susan Collins said she will be reluctant to support further rate cuts anytime soon with inflation still high and policymakers hampered by a lack of data. “I see several reasons to have a relatively high bar for additional easing in the near term,” said Collins, a voter this year on […]

Read More
Stocks making the biggest moves midday: Goldman Sachs, AMD, Oklo, Circle Internet & more
Finance

Stocks making the biggest moves midday: Goldman Sachs, AMD, Oklo, Circle Internet & more

Check out the companies making the biggest moves midday: Alkermes — The biotech company dropped 9% as traders weighed phase 2 trial results for its ALKS 2680 drug, which aims to treat narcolepsy. While the company will be advancing the drug to a Phase 3 trial, a higher range of doses or a split dosing […]

Read More